To underscore the importance of equine gastric health, during the month of August, Boehringer Ingelheim is encouraging equine veterinarians to provide client education that helps to increase awareness of the signs of EGUS.
Signs suggestive of EGUS include, but are not limited to, changes in eating and drinking behavior, weight loss, undesirable behavior, recurrent colic, dull hair coat and/or less-than-optimal performance.
If your horse is showing any of these signs, ask your veterinarian about gastroscopy, the only definitive way to diagnose stomach ulcers.
What does a gastroscopic exam entail? The Gastroscopy 101 video guides horse owners through what happens during a typical endoscopic exam of your horse's stomach.
Educational articles about EGUS are available at Ulcergard.com/GutCheck.
Veterinarians: Inform Your Clients
To host a gastric ulcer educational event, download the Gut Check toolkit at Gastrogard.com/VetResources.
Boehringer Ingelheim sales representatives can support veterinarians who are interested in educating their clients about equine gastric health, creating more opportunity to treat horses suffering from gastric ulcers.
IMPORTANT SAFETY INFORMATION: ULCERGARD can be used in horses that weigh at least 600 pounds. Safety in pregnant mares has not been determined. Not for use in humans. Keep this and all medications out of the reach of children. In case of ingestion, contact a physician.
About Boehringer Ingelheim Animal Health
Boehringer Ingelheim is the second largest animal health business in the world. The company is committed to creating animal wellbeing through its large portfolio of advanced, preventive healthcare products and services. With net sales of €3.9 billion and around 10,000 employees worldwide, Boehringer Ingelheim’s Animal Health business is present in more than 150 markets. For more information, click here.
About Boehringer Ingelheim
Boehringer Ingelheim is one of the world’s top 20 pharmaceutical companies. Headquartered in Ingelheim, Germany, the company operates globally with approximately 50,000 employees. Since its founding in 1885, the company has remained family-owned and today creates value through innovation in three business areas including human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. Boehringer Ingelheim is committed to improving lives and providing valuable services and support to patients and their families. In 2017, Boehringer Ingelheim achieved net sales of about $20.4 billion (18.1 billion euros). R&D expenditure corresponds to approximately $3.4 billion (three billion euros), or 17.0 percent of its net sales. More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in the company’s annual report at http://annualreport.boehringer-ingelheim.com.
ULCERGARD is a Merial product. Merial is now part of Boehringer Ingelheim. ®ULCERGARD is a registered trademark of Merial ©2018 Merial, Inc. Duluth, GA. All rights reserved. EQU-0618-EGUS0718.
Mitchell, R.D. Prevalence of gastric ulcers in hunter/jumper and dressage horses evaluated for poor performance. Association for Equine Sports Medicine, September 2001.
Equine Gastric Ulcer Council. Recommendations for the diagnosis and treatment of Equine Gastric Ulcer Syndrome (EGUS). Equine Vet Educ. 1999;11:262-272.